Schedule for Rating Disabilities: The Hematologic and Lymphatic Systems, 54881 [C1-2018-23517]
Download as PDF
<![CDATA[
Federal Register / Vol. 83, No. 212 / Thursday, November 1, 2018 / Rules and Regulations
Jersey Avenue SE, Washington, DC
20590; (800) 853–1351 and is available
from the sources indicated below. It is
also available for inspection at the
National Archives and Records
Administration (NARA). For
information on the availability of this
material at NARA, call 202–741–6030 or
go to www.archives.gov/federal-register/
cfr/ibr-locations.html.
(1) * * *
(ii) A Policy on Design Standards—
Interstate System, May 2016.
*
*
*
*
*
(iv) AASHTO–LRFD Bridge
Construction Specifications, 4th
Edition, copyright 2017.
(v) AASHTO LRFD–8, LRFD Bridge
Design Specifications, 8th Edition, 2017.
*
*
*
*
*
(vii) AASHTO/AWS D1.5M/D1.5:
2015–AMD1, Bridge Welding Code,
Amendment: Second Printing December
12, 2016; with
(A) AASHTO BWC–7–I1–OL, 2018
Interim Revisions to AASHTO/AWS
D1.5M/D1.5: 2015 Bridge Welding Code,
7th Edition, copyright 2017.
(B) [Reserved]
(viii) AASHTO LTS–6, Standard
Specifications for Structural Supports
for Highway Signs, Luminaires, and
Traffic Signals, 6th Edition, copyright
2013, with:
(A) AASHTO LTS–6–I1, 2015 Interim
Revisions to Standard Specifications for
Structural Supports for Highway Signs,
Luminaires, and Traffic Signals,
copyright 2014.
(B) [Reserved]
(ix) AASHTO LRFDLTS–1, LRFD
Specifications for Structural Supports
for Highway Signs, Luminaires, and
Traffic Signals, 1st Edition, copyright
2015, with:
(A) AASHTO LRFDLTS–1–I1–OL,
2017 Interim Revisions to LRFD
Specifications for Structural Supports
for Highway Signs, Luminaires, and
Traffic Signals, copyright 2016, and
(B) AASHTO LRFDLTS–1–I2–OL,
2018 Interim Revisions to LRFD
Specifications for Structural Supports
for Highway Signs, Luminaires, and
Traffic Signals, copyright 2017.
(x) 2017 Edition of Transportation
Materials, Parts 1–3, copyright 2017.
(2) American Welding Society (AWS),
8669 NW 36 Street, #130 Miami, FL
33166–6672; www.aws.org; or (800)
443–9353 or (305) 443–9353.
*
*
*
*
*
[FR Doc. 2018–23821 Filed 10–31–18; 8:45 am]
BILLING CODE 4910–22–P
DEPARTMENT OF VETERANS
AFFAIRS
38 CFR Part 4
RIN 2900–AO19
Schedule for Rating Disabilities: The
Hematologic and Lymphatic Systems
Correction
In rule 2018–23517 beginning on page
54250 in the issue of Monday, October
29, 2018, make the following correction:
§ 4.117
[Corrected]
In § 4.117, On page 54255, in the
table, entry 7703 should read as follows:
■
7703 Leukemia (except for chronic myelogenous leukemia):
When there is active disease or during a treatment phase .........................................................................................................
Otherwise rate residuals under the appropriate diagnostic code(s).
Chronic lymphocytic leukemia or monoclonal B-cell lymphocytosis (MBL), asymptomatic, Rai Stage 0 ...................................
Note (1): A 100 percent evaluation shall continue beyond the cessation of any surgical therapy, radiation therapy, antineoplastic
chemotherapy, or other therapeutic procedures. Six months after discontinuance of such treatment, the appropriate disability
rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter. If there has been no recurrence, rate on residuals.
Note (2): Evaluate symptomatic chronic lymphocytic leukemia that is at Rai Stage I, II, III, or IV the same as any other leukemia evaluated under this diagnostic code.
Note (3): Evaluate residuals of leukemia or leukemia therapy under the appropriate diagnostic code(s). Myeloproliferative Disorders: (Diagnostic Codes 7704, 7718, 7719).
[FR Doc. C1–2018–23517 Filed 10–31–18; 8:45 am]
BILLING CODE 1301–00–D
DEPARTMENT OF COMMERCE
National Oceanic and Atmospheric
Administration
50 CFR Part 679
[Docket No. 170817779–8161–02]
amozie on DSK3GDR082PROD with RULES
RIN 0648–XG477
Fisheries of the Exclusive Economic
Zone Off Alaska; Pacific Cod by
Catcher Vessels Greater Than or Equal
to 60 Feet Length Overall Using Pot
Gear in the Bering Sea and Aleutian
Islands Management Area
National Marine Fisheries
Service (NMFS), National Oceanic and
Atmospheric Administration (NOAA),
Commerce.
ACTION: Temporary rule; closure.
AGENCY:
VerDate Sep<11>2014
20:21 Oct 31, 2018
Jkt 247001
NMFS is prohibiting directed
fishing for Pacific cod by catcher vessels
greater than or equal to 60 feet (18.3
meters (m)) length overall (LOA) using
pot gear in the Bering Sea and Aleutian
Islands management area (BSAI). This
action is necessary to prevent exceeding
the 2018 Pacific cod total allowable
catch allocated to catcher vessels greater
than or equal to 60 feet (18.3m) LOA
using pot gear in the BSAI.
DATES: Effective 1200 hours, Alaska
local time (A.l.t.), October 30, 2018,
through 1200 hours, A.l.t., December 31,
2018.
FOR FURTHER INFORMATION CONTACT: Josh
Keaton, 907–586–7228.
SUPPLEMENTARY INFORMATION: NMFS
manages the groundfish fishery in the
BSAI exclusive economic zone
according to the Fishery Management
Plan for Groundfish of the Bering Sea
and Aleutian Islands Management Area
(FMP) prepared by the North Pacific
Fishery Management Council under
SUMMARY:
PO 00000
Frm 00021
Fmt 4700
Sfmt 4700
54881
100
0
authority of the Magnuson-Stevens
Fishery Conservation and Management
Act. Regulations governing fishing by
U.S. vessels in accordance with the FMP
appear at subpart H of 50 CFR part 600
and 50 CFR part 679.
The 2018 Pacific cod total allowable
catch (TAC) allocated to catcher vessels
greater than or equal to 60 feet (18.3m)
LOA using pot gear in the BSAI is
15,235 metric tons (mt) as established
by the final 2018 and 2019 harvest
specifications for groundfish in the
BSAI (89 FR 8365, February 27, 2018).
In accordance with § 679.20(d)(1)(iii),
the Administrator, Alaska Region,
NMFS (Regional Administrator), has
determined that the 2018 Pacific cod
TAC allocated as a directed fishing
allowance to catcher vessels greater than
or equal to 60 feet (18.3m) LOA using
pot gear in the BSAI will soon be
reached. Consequently, NMFS is
prohibiting directed fishing for Pacific
cod by catcher vessels greater than or
E:\FR\FM\01NOR1.SGM
01NOR1
]]>Agencies
[Federal Register Volume 83, Number 212 (Thursday, November 1, 2018)]
[Rules and Regulations]
[Page 54881]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: C1-2018-23517]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF VETERANS AFFAIRS
38 CFR Part 4
RIN 2900-AO19
Schedule for Rating Disabilities: The Hematologic and Lymphatic
Systems
Correction
In rule 2018-23517 beginning on page 54250 in the issue of Monday,
October 29, 2018, make the following correction:
Sec. 4.117 [Corrected]
0
In Sec. 4.117, On page 54255, in the table, entry 7703 should read as
follows:
------------------------------------------------------------------------
------------------------------------------------------------------------
7703 Leukemia (except for chronic myelogenous leukemia):
When there is active disease or during a treatment 100
phase..............................................
Otherwise rate residuals under the appropriate
diagnostic code(s).................................
Chronic lymphocytic leukemia or monoclonal B-cell 0
lymphocytosis (MBL), asymptomatic, Rai Stage 0.....
Note (1): A 100 percent evaluation shall continue beyond
the cessation of any surgical therapy, radiation
therapy, antineoplastic chemotherapy, or other
therapeutic procedures. Six months after discontinuance
of such treatment, the appropriate disability rating
shall be determined by mandatory VA examination. Any
change in evaluation based upon that or any subsequent
examination shall be subject to the provisions of Sec.
3.105(e) of this chapter. If there has been no
recurrence, rate on residuals..........................
Note (2): Evaluate symptomatic chronic lymphocytic
leukemia that is at Rai Stage I, II, III, or IV the
same as any other leukemia evaluated under this
diagnostic code........................................
Note (3): Evaluate residuals of leukemia or leukemia
therapy under the appropriate diagnostic code(s).
Myeloproliferative Disorders: (Diagnostic Codes 7704,
7718, 7719)............................................
------------------------------------------------------------------------
[FR Doc. C1-2018-23517 Filed 10-31-18; 8:45 am]
BILLING CODE 1301-00-D
